Regulatory Roundup: John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more.

ePT--the Electronic Newsletter of Pharmaceutical Technology

According to the FDA Press Office on Jan. 5, 2010, John Taylor, counselor to the commissioner, has been asked to serve as the acting principal deputy commissioner for the next 60 days. It was reported earlier this week that Joshua Sharfstein, principal deputy commissioner under Margaret Hamburg, was leaving the agency to work for the state of Maryland as secretary of health. Dr. Hamburg issued a memo on the subject today.

The US Pharmacopeia (USP) released proposals for universal standards to guide the content, language, format, and appearance of prescription drug labels. USP is seeking comments from pharmacists and other healthcare professionals for the newly proposed General Chapter <17> Prescription Container Labeling. Comments are due Mar. 31, 2011. The development of the proposed standards was led by the Institute of Medicine (IOM) and aim to “improve health literacy in the United States by bringing together government, industry, associations, and other groups to advance practical strategies that can be implemented to maximize patient comprehension of health information,” according to the USP notice. The core components of the standard proposals include labeling prescriptions in a patient-centered manner; emphasizing instructions and other important information; giving explicit instructions, including the purpose for use; improving readability; and limiting auxiliary information.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here